Marketing drugs, marketing health care relationships: A content analysis of visual cues in direct-to-consumer prescription drug advertising

Health Communication

Volumn 16, Issue 2, 2004, Pages 131-157

  Welch Cline, Rebecca J ^a   Young, Henry N ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; CELECOXIB; EFAVIRENZ; HYALURONIC ACID; INDINAVIR; NELFINAVIR; NEVIRAPINE; OXANDROLONE; ROFECOXIB; SAQUINAVIR; SILDENAFIL;

ARTICLE; ASSOCIATION; COGNITION; CONSUMER; DATA ANALYSIS; DOCTOR PATIENT RELATION; DRUG MARKETING; HEALTH CARE; HEALTH CARE ACCESS; HEALTH EDUCATION; HUMAN; INFORMATION; LEARNING; MASS MEDIUM; MODEL; MOTIVATION; OBSERVATION; PRESCRIPTION; THEORY;

EID: 2442573658     PISSN: 10410236     EISSN: None     Source Type: Journal    
DOI: 10.1207/S15327027HC1602_1     Document Type: Article

References (62)

1. APhA endorses manufacturers' direct-to-consumer Rx drug ads. (1988, May). American Druggist, 26, 28.
2. Avorn, J. (2000). Post-modern drug evaluation. The deconstruction of evidence-based regulation. Pharmacoeconomics, 18(Suppl. 1), 15-20.
3. Avorn, J., & Solomon, D. H. (2000). Cultural and economic factors that (mis)shape antibiotic use: The nonpharmacologic basis of therapeutics. Annals of Internal Medicine, 133, 128-135.
4. Ballard-Reisch, D. S. (1990). A model of participative decision making for physician-patient interaction. Health Communication, 2, 91-104.
5. Bandura, A. (1977). Social learning theory. Englewood Cliffs, NJ: Prentice Hall.
6. Bandura, A. (1994). Social cognitive theory of mass communication. In J. Bryant & D. Zillman (Eds.), Media effects: Advances in theory and research (pp. 61-90). Hillsdale, NJ: Lawrence Erlbaum Associates, Inc.
7. Beisecker, A. E., & Beisecker, T. D. (1993). Using metaphors to characterize doctor-patient relationships: Paternalism versus consumerism. Health Communication, 5, 41-58.
8. Bell, R. A., Kravitz, R. L., & Wilkes, M. S. (2000). Direct-to-consumer prescription drug advertising, 1989-1998: A content analysis of conditions, targets, inducements, and appeals. The Journal of Family Practice, 49, 329-335.
9. Birdwhistell, R. (1955). Background to kinesics. ETC, 13, 10-18.
10. Bowman, L. (2001, April 11). Prescription drug abuse rising. The Chicago Sun-Times, p. 3.
11. Bradley, L. R., & Zito, J. M. (1997). Direct-to-consumer prescription drug advertising. Medical Care, 35, 86-92.
12. Butterfield, F. (2001, July 7). Theft of painkiller reflects popularity on the street. The New York Times, p. 6.
13. Centers for Disease Control and Prevention. (2001, December). HIV/AIDS surveillance report, 13(1). Atlanta, GA: U.S. Department of Health and Human Services.
14. Charmaz, K. (1991). Good days, bad days: The self in chronic illness and time. New Brunswick, NJ: Rutgers University Press.
15. Clark, R. A., & Delia, J. D. (1979). Topoi and rhetorical competence. The Quarterly Journal of Speech, 65, 187-206.
16. Cline, R. J. W. (2003). Everyday interpersonal communication and health. In T. L. Thompson, R. L. Parrott, A. Dorsey, & K. Miller (Eds.), Handbook of health communication (pp. 285-313). Mahwah, NJ: Lawrence Erlbaum Associates, Inc.
17. Cline, R. J. W., & McKenzie, N. J. (1996). Women and AIDS: The lost population. In R. L. Parrott & C. M. Condit (Eds.), Evaluating women's health messages: A resource book (pp. 382-401). Thousand Oaks, CA: Sage.
18. Conrad, P. (1985). The meaning of medications: Another look at compliance. Social Science and Medicine, 20, 29-37.
19. Conrad, P., & Schneider, J. W. (1980). Deviance and medicalisation: From badness to sickness. St. Louis, MO: Mosby.
20. Conrad, P., & Stewart, M. A. (1976). Identifying hyperactive children: The medicalization of deviant behavior. Lexington, MA: Lexington.
21. Corbin, J. M., & Strauss, A. (1988). Unending work and care. San Francisco: Jossey-Bass.
22. Deceptively upbeat AIDS ads must stop, FDA says. (2001, April 30). San Francisco Chronicle, p. A1.
23. Growth seen in ads for direct-to-consumer drugs. (1997, April 27). AMA News, p. 16.
24. Henry J. Kaiser Family Foundation. (2001, November). Understanding the effects of direct-to-consumer prescription drug advertising (Document No. 3197). Menlo Park, CA: Author.
25. Hilts, P. J. (2001, June 8). Jury awards $6.4 million in killings tied to drug. The New York Times, p. A18.
26. Hoffman, J. R., & Wilkes, M. (1999). Direct to consumer advertising of prescription drugs. An idea whose time should not come [Editorial]. British Medical Journal, 318, 1301-1302.
27. Hollon, M. F. (1999). Direct-to-consumer marketing of prescription drugs: Creating consumer demand. Journal of the American Medical Association, 281, 382-384.
28. Holmer, A. F. (1999). Direct-to-consumer prescription drug advertising builds bridges between patients and physicians. Journal of the American Medical Association, 281, 380-382.
29. Hunt, M. (1998, April). Direct-to-consumer advertising of prescription drugs (Background paper, National Health Policy Forum). Washington, DC: George Washington University.
30. Karp, D. A. (1996). Speaking of sadness: Depression, disconnection, and the meanings of illness. New York: Oxford University Press.
31. Katz, W. A. (1997). Magazines for libraries. New Providence, NJ: Bowker.
32. King, W. (2001, March 15). New HIV warning for King County; unsafe sex rising, health officials say. Seattle Times, p. A1.
33. Kravitz, R. L. (2000). Direct-to-consumer advertising of prescription drugs: These ads present both perils and opportunities. The Western Journal of Medicine, 173, 221-222.
34. La Puma, J. (1998). Direct-to-consumer advertising: Helpful or harmful - Or maybe both. Managed Care, 7(4), 72-73.
35. Lipsky, M. S., & Taylor, C. A. (1997). The opinions and experiences of family physicians regarding direct-to-consumer advertising. Journal of Family Practice, 45, 495-499.
36. Lurie, P., & Wolfe, S. M. (1998, December 30). Troubling climate at FDA. The Washington Post, p. A19.
37. Madhaven, S. (1993, Winter). Are we ready for direct to consumer advertising of prescription drugs? Pharmacy Business, 14-28.
38. Medawar, C. (2001, December). Health, pharma, and the EU: A briefing for members of the European Parliament on direct-to-consumer drug promotion. Retrieved February 15, 2002, from http://www.socialaudit.org.uk/5111-005. htm#1HEALTH
39. Messaris, P. (1994). Visual literacy: Image, mind, and reality. Boulder, CO: Westview.
40. Montagne, M. (1996). Social aspects of pharmaceutical development. In B. Bleidt & M. Montagne (Eds.), Clinical research and pharmaceutical development (pp. 317-336). New York: Marcel Dekker.
41. Morgan, C., & Levy, D. (1998). To their health. Brandweek, 39, 30-33.
42. National Center for Health Statistics. (2000, July 24). National vital statistics reports, 48(11). Atlanta, GA: Centers for Disease Control and Prevention, U. S. Department of Health and Human Services.
43. Newton, D. A., & Burgoon, J. K. (1990). The use and consequences of verbal influence strategies during interpersonal disagreements. Human Communication Research, 16, 477-518.
44. O'Brien, W. M. (1982). Alleged direct promotion of prescription drugs to consumers [Letter to the editor]. The New England Journal of Medicine, 306, 181-182.
45. Office of Disease Prevention and Health Promotion. (2000). Healthy people 2010 (2nd ed.). Washington, DC: Department of Health and Human Services.
46. O'Keefe, D. J. (1990). Elaboration likelihood model. In Persuasion: Theory and research (pp. 95-116). Newbury Park, CA: Sage.
47. Perri, M., III, Shinde, S., & Banavali, R. (1999). The past, present, and future of direct-to-consumer prescription drug advertising. Clinical Therapeutics, 21, 1798-1811.
48. Physicians say direct-to-consumer advertising affects patient behavior. (1993, July). American Journal of Hospital Pharmacy, 50, 1329.
49. Pines, W. L. (2000). Direct-to-consumer advertising. The Annals of Pharmacology, 34, 1341-1344.
50. Pinto, M. B. (2000). On the nature and properties of appeals used in direct-to-consumer advertising of prescription drugs. Psychological Reports, 86, 597-606.
51. Pinto, M. B., Pinto, J. K., & Barber, J. C. (1998). The impact of pharmaceutical direct advertising: Opportunities and obstructions. Health Marketing Quarterly, 15(4), 89-101.
52. Prather, J., & Fidell, L. S. (1975). Sex differences in the content and style of medical advertisements. Social Science and Medicine, 9, 23-26.
53. Rootman, I., & Hershfield, L. (1994). Health communication research: Broadening the scope. Health Communication, 6, 69-72.
54. Sasich, L. (1999). Peddling pills: The rise of direct-to-consumer prescription drug advertising and the dangers to consumers. Multinational Monitor, 20(1-2), 23-26.
55. Schooler, C., Basil, M. D., & Altman, D. G. (1996). Alcohol and cigarette advertising and billboards: Targeting with social cues. Health Communication, 8, 109-129.
56. Sellers, J. A. (2000). The two faces of direct-to-consumer advertising. American Journal of Health-Systems Pharmacy, 51, 1401.
57. Spurgeon, D. (1999). Doctors feel pressurised by direct to consumer advertising. British Medical Journal, 319, 1321.
58. Szasz, T. S., & Hollender, M. H. (1956). The basic models of the doctor-patient relationship. Archives in Internal Medicine, 97, 585-592.
59. Waltermire, R. D. (1998). Direct-to-consumer advertising of Rx drugs can be harmful to your health. Drug Benefit Trends, 10(10), 60-61.
60. Wang, J. J., Ausiellom, J. C., & Stafford, R. S. (1999). Trends in antihypertensive drug advertising, 1985-1996. Circulation, 99, 2055-2057.
61. Wilke, M. (1997, January 13). Ad fever sweeps healthcare industry. Advertising Age, pp. 17-19.
62. Wilkes, M. S., Bell, R. A., & Kravitz, R. L. (2000). Direct-to-consumer prescription drug advertising: Trends, impact, and implications. Health Affairs, 19, 110-128.